Literature DB >> 16862591

Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons.

Anthony H V Schapira1, Michael W J Cleeter, John R Muddle, Jane M Workman, J Mark Cooper, Rosalind H M King.   

Abstract

Dysfunction of the ubiquitin-proteasomal system (UPS) has been implicated in the pathogenesis of Parkinson's disease. The systemic administration of UPS inhibitors has been reported to induce nigrostriatal cell death and model Parkinson's disease pathology in rodents. We administered a synthetic, specific UPS inhibitor (PSI) subcutaneously to rats and quantified substantia nigral tyrosine hydroxylase-positive dopaminergic neurons by stereology. PSI caused a 15% decrease in UPS activity at 2 weeks and a 42% reduction in substantia nigra pars compacta tyrosine hydroxylase-positive neurons at 8 weeks. Systemic inhibition of the UPS warrants further evaluation as a means to model Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862591     DOI: 10.1002/ana.20934

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.

Authors:  Naoto Kadoguchi; Masahiro Umeda; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2008-03-14       Impact factor: 5.046

3.  Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.

Authors:  Chaoshi Niu; Jiaming Mei; Qi Pan; Xianming Fu
Journal:  Stereotact Funct Neurosurg       Date:  2009-02-18       Impact factor: 1.875

4.  A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Authors:  Shubhangi Prabhudesai; Sharmistha Sinha; Aida Attar; Aswani Kotagiri; Arthur G Fitzmaurice; Rajeswari Lakshmanan; Ravi Lakshmanan; Magdalena I Ivanova; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Mark Stahl; Gal Bitan; Jeff M Bronstein
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

5.  Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.

Authors:  Arthur P Chou; Nigel Maidment; Rebecka Klintenberg; John E Casida; Sharon Li; Arthur G Fitzmaurice; Pierre-Olivier Fernagut; Farzad Mortazavi; Marie-Francoise Chesselet; Jeff M Bronstein
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

6.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Authors:  Brian N Mathur; M Diana Neely; Melanie Dyllick-Brenzinger; Anurag Tandon; Ariel Y Deutch
Journal:  Brain Res       Date:  2007-07-20       Impact factor: 3.252

7.  Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.

Authors:  Naoto Kadoguchi; Hiroki Kimoto; Ryohei Yano; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2008-04-19       Impact factor: 3.584

8.  Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.

Authors:  Takuya Oshikawa; Hayato Kuroiwa; Ryohei Yano; Hironori Yokoyama; Naoto Kadoguchi; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2009-04-16       Impact factor: 5.046

9.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

10.  Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.

Authors:  Faneng Sun; Arthi Kanthasamy; Chunjuan Song; Yongjie Yang; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.